Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD
Crossref DOI link: https://doi.org/10.1186/s12916-015-0398-0
Published Online: 2015-07-02
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Puhan, Milo A.
Yu, Tsung
Boyd, Cynthia M.
ter Riet, Gerben
License valid from 2015-07-02